MedPath
Found 1 clinical trials|View Analysis
Sort by:

Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus

Phase 3
Recruiting
Conditions
Uremic Pruritus
Interventions
Drug: QLG2198
Drug: Placebo
First Posted Date
2024-06-06
Last Posted Date
2024-06-21
Lead Sponsor
Qilu Pharmaceutical (Hainan) Co., Ltd.
Target Recruit Count
194
Registration Number
NCT06446310
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

🇨🇳

Jieyang People's Hospital, Jieyang, Guangdong, China

🇨🇳

Shandong Provincial Hospital, Jinan, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath